Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Cancer type

Myeloma

Multiple myeloma.

Must-know

  1. 1

    MASTER: MRD-adapted therapy in newly diagnosed myeloma

    Costa et al. The Lancet Haematology. 2023.

    123 patients received quadruplet therapy with treatment stopped after two consecutive MRD-negative results. Of 118 with evaluable MRD, 96 (81%) reached MRD below 10⁻⁵ and 84 (71%) stopped therapy. 36-month progression-free survival was 88% with no high-risk cytogenetic abnormality, 79% with one, and 50% with two or more.

    PMID 37776872DOI

Listed when a study is a randomized or prospective interventional ctDNA or MRD trial, is cited in NCCN or ESMO guidance, or is a prospective validation cohort in a high-impact journal. Shorter lists mean fewer studies met that rule. No test is ranked.

Publications and presentations

Presentations

  • Level 3prognosticASCO Annual Meeting 2021

    Personalized, ctDNA analysis to detect minimal residual disease and identify patients at high risk of relapse with multiple myeloma.

    Dhakal, Binod · Abstract 8029 · 28 patients after upfront autologous transplant; 80 plasma timepoints; median follow-up 92.4 months; single-center retrospective

    Signatera (personalized tumor-informed mPCR-NGS), assessed about 3 months after transplant; bone-marrow comparison used multiparameter flow cytometry at 10^-4

    ctDNA was detectable in 17/24 (70.8%) before transplant, 15/28 (53.6%) at about 3 months after transplant, and 11/28 (39.2%) during later surveillance. Of 15 patients MRD-positive at 3 months, 14 (93.3%) later relapsed (HR 5.64, 95% CI 1.8-17, P=0.0003). Median PFS was 84 months if ctDNA-negative at 3 months vs 31 months if positive (P=0.003). The 3-month positive predictive value for relapse was 93.3%, higher than marrow flow cytometry (68.4%) in this series.

    Abstract

Accruing studies for Myeloma

Trials

Multiple myeloma MRD milestones

  1. December 23, 2019

    Registration of the #mmMRD healthcare hashtag on Symplur

    Benjamin A. Derman (@bdermanmd). Symplur Healthcare Hashtag Project

    The archived Symplur page, with a page date of December 23, 2019, states that #mmMRD is a healthcare hashtag submitted by @bdermanmd and defines it as multiple myeloma minimal residual disease and measurable residual disease. The original Symplur page is offline and redirects to the Symplur homepage.

  2. June 7, 2020

    Clinician attitudes and practices toward measurable residual disease in multiple myeloma.

    Benjamin A. Derman, Jagoda K. Jasielec, Andrzej J. Jakubowiak. Br J Haematol. 2020 Aug;190(3):470-472. Letter. PMID 32506429.

    Letter in the British Journal of Haematology. First published online June 7, 2020. The print citation is Br J Haematol. 2020 Aug;190(3):470-472.

  3. July 11, 2022

    Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma.

    Benjamin A. Derman, Andrzej J. Jakubowiak, Michael A. Thompson. Blood Cancer J. 2022 Jul 11;12(7):108. Letter. Open access (CC BY 4.0). PMID 35821020.

    Letter in Blood Cancer Journal, published July 11, 2022. The official title uses the words measurable residual disease-guided.

  4. January 6, 2024

    Measurable Residual Disease and Decision-Making in Multiple Myeloma.

    Benjamin A. Derman, Rafael Fonseca. Hematol Oncol Clin North Am. 2024 Apr;38(2):477-495. Review. PMID 38184470.

    Review in Hematology/Oncology Clinics of North America. Electronic publication January 6, 2024. The print issue is April 2024, volume 38, issue 2, pages 477-495.

  5. April 12, 2024

    FDA Oncologic Drugs Advisory Committee voted 12-0 that the evidence supports the use of MRD as an accelerated-approval endpoint in multiple myeloma clinical trials.

    U.S. FDA Oncologic Drugs Advisory Committee meeting, April 12, 2024

    On April 12, 2024, ODAC voted Yes 12, No 0, Abstain 0 on the question: Does the evidence support the use of MRD as an accelerated approval endpoint in MM clinical trials? The FDA summary minutes were approved July 2, 2024.

    IMF account of the vote

  6. June 3, 2024

    Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).

    Benjamin Avi Derman, Jennifer H. Cooperrider, Tadeusz Kubicki, Ajay Major, Ken Jiang, Aubrianna Ramsland, Karson Buckley, Samrawit Melka, Amanda McIver, Theodore Karrison, Andrzej J. Jakubowiak. 2024 ASCO Annual Meeting, Abstract 106. Clinical Science Symposium, 'Use of MRD-Guided Strategies to Optimize Therapeutic Interventions.' Presented June 3, 2024, 10:01-10:13 a.m., Hall D1, Chicago. Citation: J Clin Oncol 42, 2024 (suppl 16; abstr 106).

    2024 ASCO Annual Meeting abstract 106, presented June 3, 2024. Trial NCT04108624 (MRD2STOP). A later paper with the same title was published in Blood Cancer Journal on October 7, 2024. Slide and webcast files on the ASCO page were not confirmed to be available without an ASCO login.

    Blood Cancer Journal paper, PMID 39375362ClinicalTrials.gov NCT04108624

  7. September 17, 2025

    Meet the Experts: MRD in clinical practice

    Ben Derman, Noemi Puig. 22nd International Myeloma Society Annual Meeting, Toronto, Canada. Wednesday, September 17, 2025, 12:00-12:50, Room 714B.

    22nd International Myeloma Society Annual Meeting, Toronto. Wednesday, September 17, 2025, 12:00-12:50, Room 714B. Presenters listed in the program: Ben Derman and Noemi Puig. No official slide deck or webcast URL was found.

Myeloma MRD assays

Sensitivity is quoted as stated for each method. Mass-spectrometry assays measure M-protein in blood. They are not a cellular 10^-6 bone-marrow limit of detection.

AssaySampleMethodSensitivity as stated
EuroFlow next-generation flow (NGF)

EuroFlow Consortium

Bone marrowStandardized 2-tube 8-color flow cytometry (NGF)LOD <2×10^-6 (≥20 aberrant plasma cells among 10^7 events) and LOQ <5×10^-6 when ≥10^7 cells are acquired; 10^-5 is a commonly reported clinical cutoff
clonoSEQ

Adaptive Biotechnologies

Bone marrow (MM and B-ALL at original 2018 authorization); later authorized for CLL including peripheral bloodNGS of immunoglobulin receptor rearrangements (multiplex PCR + sequencing)Claimed ability to detect down to 1 residual cell in 1,000,000 (10^-6), as described in the 2018 FDA authorization
M-inSight

Sebia

Peripheral blood (serum)Personalized targeted mass spectrometry of clonotypic M-protein peptidesMethod papers report mass-concentration sensitivity on the order of 10^-5 g/dL, substantially more sensitive than SPEP/IFE; not a cellular 10^-6 marrow assay
EasyM

Rapid Novor

Peripheral blood (serum)Clonotypic mass spectrometry tracking patient-specific M-protein peptidesCompared with EuroFlow BM MRD in Haematologica 2025 (PMID 39506908) and described in Clin Cancer Res 2024 (PMID 38170583)
MASS-FIX / quantitative MASS-FIX (Mayo Clinic)

Mayo Clinic Laboratories

Serum (and related specimens for M-protein detection)MALDI-TOF mass spectrometry for detection/isotyping (and later quantification) of monoclonal proteinsMore sensitive than conventional SPEP/IFE; used at Mayo to replace IFE and, later, SPEP. Not equivalent to 10^-6 BM MRD.
EXENT

The Binding Site (Thermo Fisher Scientific)

SerumAutomated MALDI-TOF mass spectrometry for detection and isotyping of intact IgG, IgA, and IgM M-proteinsAnalytically more sensitive than SPEP/IFE. FDA 510(k) K250159 clearance is for diagnosis/isotyping of M-proteins, not as an MRD IVD equivalent to NGS/NGF. Added as a major commercial mass-spectrometry platform. Not interchangeable with BM MRD.
GenoPredicta (Predicta Biosciences)

Predicta Biosciences

Peripheral blood (circulating myeloma cells)NGS / whole-genome sequencing of isolated circulating tumor cells, per company materialsA peer-reviewed standard 10^-5 or 10^-6 MRD LOD was not independently verified for this review Emerging PB NGS approach; numeric LOD not recorded as verified.

Regulatory timeline

  1. 2018-09-28

    FDA authorizes clonoSEQ, the first NGS-based MRD test for multiple myeloma and B-cell ALL

    On September 28, 2018, FDA granted De Novo authorization for Adaptive Biotechnologies' clonoSEQ assay to detect and monitor MRD in bone-marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia, with the agency describing detection of remaining cancer cells at very low levels (down to about 1 in 1,000,000 cells).

  2. 2024-04-12

    FDA Oncologic Drugs Advisory Committee vote on MRD as an accelerated-approval endpoint in multiple myeloma

    ODAC voted Yes 12, No 0, Abstain 0 on: 'Does the evidence support the use of MRD as an accelerated approval endpoint in MM clinical trials?' Committee discussion supported use in both newly diagnosed and relapsed/refractory settings, with 9-month, 12-month, and MRD-negative CR at any time considered acceptable assessment timepoints. Minutes approved July 2, 2024.

  3. 2026-01-20

    Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval (Draft Guidance for Industry)

    Draft guidance, posted on the FDA site on January 20, 2026 (Federal Register notice January 21, 2026). Recommends MRD-negativity rate (in patients who have achieved CR or stringent CR), assessed in bone marrow by flow or sequencing, and CR rate as primary endpoints to support accelerated approval. MRD negativity should be assessed at a threshold of at least 1 in 10^5 residual tumor cells; alternate thresholds require justification. Verification of clinical benefit (typically PFS or OS) will generally be required, and confirmatory trial(s) should generally be underway prior to accelerated approval. Comments were due March 23, 2026.

  4. 2026-08-13

    FDA accelerated approval of iberdomide (Zenbexus) with daratumumab and hyaluronidase-fihj and dexamethasone

    Accelerated approval on August 13, 2026, for adults with multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, in combination with daratumumab and hyaluronidase-fihj and dexamethasone. In the first 420 randomized patients (IberDd n=207 vs DVd n=213), MRD-negative CR at any time was 41% (95% CI 34-48) vs 21% (95% CI 15-27), p<0.0001. Continued approval may depend on confirmatory verification of clinical benefit. The trial remains ongoing for PFS.

Myeloma

25 records

  • Level 1myelomapositive2024 · 2024-04-12

    FDA Oncologic Drugs Advisory Committee vote on MRD as an accelerated-approval endpoint in multiple myeloma

    Oncologic Drugs Advisory Committee, U.S. Food and Drug Administration. FDA ODAC meeting minutes.

    ODAC voted Yes 12, No 0, Abstain 0 on: 'Does the evidence support the use of MRD as an accelerated approval endpoint in MM clinical trials?' Committee discussion supported use in both newly diagnosed and relapsed/refractory settings, with 9-month, 12-month, and MRD-negative CR at any time considered acceptable assessment timepoints. Minutes approved July 2, 2024.

    IMF account of the vote

  • Level 1myelomapositive2026 · 2026-01-20

    Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval (Draft Guidance for Industry)

    U.S. Food and Drug Administration (OCE, CDER, CBER, CDRH). FDA draft guidance; Docket FDA-2025-D-2616. Bone-marrow flow cytometry or sequencing; threshold of at least 1 in 10^5

    Draft guidance, posted on the FDA site on January 20, 2026 (Federal Register notice January 21, 2026). Recommends MRD-negativity rate (in patients who have achieved CR or stringent CR), assessed in bone marrow by flow or sequencing, and CR rate as primary endpoints to support accelerated approval. MRD negativity should be assessed at a threshold of at least 1 in 10^5 residual tumor cells; alternate thresholds require justification. Verification of clinical benefit (typically PFS or OS) will generally be required, and confirmatory trial(s) should generally be underway prior to accelerated approval. Comments were due March 23, 2026.

    PDFFederal Register notice

  • Level 1myelomapositive2026 · 2026-08-13

    FDA accelerated approval of iberdomide (Zenbexus) with daratumumab and hyaluronidase-fihj and dexamethasone

    U.S. Food and Drug Administration. FDA Cancer Approvals. MRD-negative complete response at any time (EXCALIBER-RRMM) · n=420

    Accelerated approval on August 13, 2026, for adults with multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, in combination with daratumumab and hyaluronidase-fihj and dexamethasone. In the first 420 randomized patients (IberDd n=207 vs DVd n=213), MRD-negative CR at any time was 41% (95% CI 34-48) vs 21% (95% CI 15-27), p<0.0001. Continued approval may depend on confirmatory verification of clinical benefit. The trial remains ongoing for PFS.

    Prescribing information

  • Level 1myeloma/ALLpositive2018 · 2018-09-28

    FDA authorizes clonoSEQ, the first NGS-based MRD test for multiple myeloma and B-cell ALL

    U.S. Food and Drug Administration. FDA press announcement (De Novo DEN170080). clonoSEQ NGS, bone marrow

    On September 28, 2018, FDA granted De Novo authorization for Adaptive Biotechnologies' clonoSEQ assay to detect and monitor MRD in bone-marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia, with the agency describing detection of remaining cancer cells at very low levels (down to about 1 in 1,000,000 cells).

    De Novo decision summary

  • Consensusmyelomapositive2016

    International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, et al.. Lancet Oncol. PMID 27511158. Flow cytometry or sequencing MRD, with or without imaging

    IMWG defined MRD-negativity response categories (with or without imaging-based absence of extramedullary disease) to allow uniform reporting, using bone-marrow flow or sequencing plus sensitive imaging, on top of conventional CR.

  • Level 2myelomapositive2017

    Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis

    Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al.. JAMA Oncol. PMID 27632282. Heterogeneous MRD methods across included studies · n=1,273 (PFS, 14 studies); 1,100 (OS, 12 studies)

    Among 21 eligible studies, MRD negativity was associated with better PFS (HR 0.41, 95% CI 0.36-0.48, P<.001) and OS (HR 0.57, 95% CI 0.46-0.71, P<.001). In patients already in conventional CR, PFS HR was 0.44 (0.34-0.56) and OS HR 0.47 (0.33-0.67).

    Full text

  • Level 3myelomapositive2017

    Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al.. Leukemia. PMID 28104919. EuroFlow NGF, bone marrow · n=110

    EuroFlow 2-tube 8-color NGF with acquisition of ≥10^7 cells; LOD <2×10^-6 and LOQ <5×10^-6. In 110 BM samples from patients in VGPR or CR, MRD-positive rate was 47% by NGF vs 34% by conventional 8-color flow (P=0.003); 25% of conventional MRD-negative cases were NGF-positive. NGF MRD-negative vs MRD-positive CR patients had longer PFS (75% PFS not reached vs 7 months; P=0.02).

    Full text

  • Level 2myelomapositive2020

    A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

    Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al.. Blood Adv. PMID 33284948. Heterogeneous (flow and sequencing) across 44 studies · n=8,098 (PFS, 44 studies); 4,297 (OS, 23 studies)

    MRD negativity vs positivity improved PFS (HR 0.33, 95% CI 0.29-0.37, P<.001) and OS (HR 0.45, 95% CI 0.39-0.51, P<.001), including across newly diagnosed and relapsed/refractory disease, MRD thresholds, cytogenetic risk, and method of assessment.

    Full text

  • Level 2myelomapositive2020

    Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

    Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al.. Blood. PMID 32325490. MRD (NGS, 10^-5) as a key secondary endpoint · n=207

    Randomized phase 2 trial of D-RVd vs RVd in 207 transplant-eligible NDMM patients. Primary endpoint, sCR by the end of post-ASCT consolidation, was 42.4% vs 32.0% (OR 1.57, 95% CI 0.87-2.82; 1-sided P=0.068), meeting the prespecified 1-sided alpha of 0.10. With median follow-up 22.1 months, sCR improved to 62.6% vs 45.4% (P=0.0177) and MRD negativity (10^-5, ITT) was 51.0% vs 20.4% (P<.0001). 24-month PFS 95.8% vs 89.8%. MRD analysis of a randomized phase 2 trial (level 2), not MRD-guided therapy.

    Full text

  • Level 2myelomamixed2022

    Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma: The MASTER Trial (primary analysis)

    Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al.. J Clin Oncol. PMID 34898239. NGS MRD (clonoSEQ lineage), 10^-5 primary; 10^-6 also reported · n=123

    Single-arm phase 2 MRD-adapted Dara-KRd with AHCT (n=123). Primary endpoint MRD <10^-5: 80% overall (78%, 82%, and 79% for 0, 1, and 2+ HRCAs); 66% reached MRD <10^-6; 71% had two consecutive MRD-negative assessments and entered treatment-free surveillance. Two-year PFS was 87% (91%, 97%, and 58% for 0, 1, and 2+ HRCAs). 12-month incidence of MRD resurgence or progression after cessation was 4%, 0%, and 27% by HRCA group. Not a randomized trial, so filed as level 2 despite being MRD-guided.

  • Level 2myelomamixed2023

    Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

    Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al.. Lancet Haematol. PMID 37776872. NGS MRD, 10^-5 (MRD-evaluable n=118 of 123) · n=123

    Final analysis, median follow-up 42.2 months. Of 118 MRD-evaluable patients, 96 (81%, 95% CI 73-88) reached MRD <10^-5 and 84 (71%, 62-79) reached MRD-SURE and stopped therapy. 36-month PFS: 88% (no HRCA), 79% (1 HRCA), 50% (2+ HRCAs). Among 84 who stopped therapy, 24-month cumulative incidence of progression from cessation was 9%, 9%, and 47% by HRCA group. MRD-adapted cessation was feasible in 0-1 HRCA disease; patients with 2+ HRCAs had higher progression after stopping.

    Full text

  • Level 2myelomapositive2022

    Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): a randomised, open-label, multicentre, phase 3 trial

    Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, et al.. Lancet Haematol. PMID 36328040. Flow-cytometry MRD after induction (primary endpoint of part 1) · n=660

    Phase 3, 660 transplant-eligible NDMM patients (331 Isa-VRd, 329 VRd) in Germany. MRD negativity after induction (ITT) was reached in 166 (50%) vs 117 (36%) (OR 1.82, 95% CI 1.33-2.48; p=0.00017). Grade 3-4 neutropenia 23% vs 7%. MRD analysis of an RCT (level 2), not MRD-guided therapy. NCT03617731.

  • Level 2myelomapositive2025

    Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial

    Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, et al.. J Clin Oncol. PMID 39652594. MRD after Isa-VRd vs VRd induction · n=662

    Final part 1 analysis of GMMG-HD7 (331 Isa-RVd, 329 RVd). MRD-negativity rates continued to deepen after transplant (66% Isa-RVd vs 48% RVd). Isa-RVd induction significantly prolonged PFS vs RVd regardless of maintenance (HR 0.70, 95% CI 0.52-0.95, P=0.0184). Level 2 (MRD and PFS analysis of a randomized trial).

    Full text

  • Level 2myelomapositive2024

    Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma (PERSEUS)

    Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al.. N Engl J Med. PMID 38084760. MRD negativity as a key secondary endpoint (threshold as prespecified in the protocol; reported as MRD-negative status) · n=709

    Phase 3 trial, 709 transplant-eligible NDMM patients randomized to D-VRd (with D-R maintenance) vs VRd (with R maintenance). At median follow-up 47.5 months, 48-month PFS was 84.3% vs 67.7% (HR 0.42, 95% CI 0.30-0.59, P<0.001). CR or better 87.9% vs 70.1% (P<0.001); MRD-negative status 75.2% vs 47.5% (P<0.001). MRD analysis of an RCT (level 2), not MRD-guided therapy.

  • Level 2myelomapositive2024

    EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

    Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, et al.. Blood. PMID 38768337. MRD negativity at 12±3 months (trial-level and individual-level association with PFS) · n=4907

    FDA-aligned meta-analysis of 8 newly diagnosed MM randomized trials (n=4,907). Trial-level association between 12-month MRD negativity and PFS: R²_WLSiv 0.67 (95% CI 0.43-0.91) and R²_copula 0.84 (0.64 to >0.99). Individual-level global OR for 12-month MRD negativity and PFS was 4.02 (95% CI 2.57-5.46) in NDMM and 7.67 (4.24-11.10) in 4 relapsed/refractory studies. Supported the case that a treatment effect on MRD is reasonably likely to predict a treatment effect on PFS. One of the two meta-analyses presented at the April 2024 ODAC.

    Full text

  • Level 2myelomapositive2025

    Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials (i2TEAMM)

    Shi Q, Paiva B, Pederson LD, Dimier N, Talpes E, Prior TJ, et al.. J Clin Oncol. PMID 39938021. MRD-negative CR at 10^-5, at 9 or 12 months · n=4773

    Individual-patient meta-analysis from 20 randomized trials; 11 studies (4,773 patients) evaluated 9- or 12-month MRD-CR at a 10^-5 threshold as an intermediate endpoint for PFS/OS in ND transplant-eligible, ND transplant-ineligible, and RRMM. Patient-level global ORs for MRD-CR and PFS ranged from 3.06 to 16.24 (all 95% CIs excluded 1.0). Trial-level R² 0.61-0.70 overall and 0.67-0.78 in newly diagnosed disease. Supported use of 9- or 12-month MRD-CR at 10^-5 as an intermediate endpoint for accelerated approval. This is the i2TEAMM pooled analysis presented at ODAC.

  • Level 2myelomapositive2025

    Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

    Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, et al.. Blood. PMID 39841461. NGS MRD at 10^-5 and 10^-6 after Isa-KRd induction · n=791

    Induction analysis of the MRD-adapted MIDAS trial: 791 patients received six 28-day cycles of Isa-KRd. 96% completed induction; best ORR 95%; 91% achieved VGPR or better. In the ITT population, MRD-negativity rates after induction were 63% at 10^-5 and 47% at 10^-6.

    Full text

  • Level 1myelomamixed2025

    Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma (MIDAS)

    Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, et al.. N Engl J Med. PMID 40459097. NGS MRD, 10^-5 to assign consolidation; primary endpoint 10^-6 MRD negativity before maintenance · n=485 MRD-negative at 10^-5 after induction; 233 MRD-positive at 10^-5

    Phase 3 randomized MRD-guided consolidation after Isa-KRd induction. Among 485 patients MRD-negative at 10^-5 after induction, premaintenance MRD negativity at 10^-6 was 86% with ASCT + 2 cycles Isa-KRd vs 84% with 6 cycles Isa-KRd without ASCT (adjusted RR 1.02, 95% CI 0.95-1.10, P=0.64). Among 233 patients MRD-positive at 10^-5, premaintenance 10^-6 negativity was 32% with tandem ASCT vs 40% with single ASCT + Isa-KRd (adjusted RR 0.82, 95% CI 0.58-1.15, P=0.31). Median follow-up about 16-17 months. Neither intensification strategy significantly improved the 10^-6 MRD endpoint. Level 1 (randomized MRD-guided trial).

    Full text

  • Level 3myelomamixed2024

    Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

    Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, Kubicki T, Jakubowiak AJ. Blood Cancer J. PMID 39375362. Multimodal: PET, BM flow (LoD 10^-5), BM clonoSEQ (LoD 10^-6), plus CD138-enriched clonoSEQ toward 10^-7 · n=47

    Pragmatic trial: 47 patients with prior MRD <10^-5, ≥1 year of maintenance, and prospectively confirmed undetectable disease by PET, BM flow (10^-5), and BM clonoSEQ (10^-6) discontinued maintenance (median prior maintenance 36 months). Median post-discontinuation follow-up 30 months. Baseline MRD ≥10^-7 in 9/47 (19%). Estimated 3-year cumulative incidence of disease resurgence was 20% if baseline MRD <10^-7 vs 75% if ≥10^-7 (HR 7.8, 95% CI 2.2-27.6, P=0.001); 3-year PFS 92% vs 49% (HR 10.1, 95% CI 1.6-62.3). Small single-arm study (level 3).

    Full textASCO abstract 106ClinicalTrials.gov NCT04108624

  • Level 2myelomapositive2025

    Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

    Corre J, Vincent L, Moreau P, Hebraud B, Hulin C, Béné MC, et al.. Blood. PMID 40127397. MRD at 10^-5 and 10^-6 at prespecified time points

    Long-term MRD and PFS after median follow-up 80.1 months. D-VTd improved MRD-negativity (10^-5) after induction (34.6% vs 23.1%) and consolidation (63.7% vs 43.7%) vs VTd. Daratumumab maintenance (fixed duration ≤2 years vs observation; not MRD-guided) further improved MRD-negativity (D-VTd/dara vs D-VTd/observation: 10^-5 77.3% vs 70.7%, 10^-6 60.7% vs 52.0%; VTd/dara vs VTd/observation: 10^-5 70.9% vs 51.2%, 10^-6 48.4% vs 30.7%) and provided PFS benefit regardless of post-consolidation MRD status. Correction: this is not an MRD-guided maintenance trial.

    Full text

  • Level 2myelomapositive2025

    Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

    Usmani SZ, Facon T, Hungria V, Bahlis NJ, et al.. Nat Med. PMID 39910273. MRD negativity (and sustained MRD negativity) as a key endpoint · n=395

    Phase 3 D-VRd vs VRd in transplant-ineligible or transplant-deferred NDMM. At median follow-up 58.7 months, MRD-negativity rate 60.9% vs 39.4% (OR 2.37, 95% CI 1.58-3.55, P<0.0001); ≥CR 81.2% vs 61.6% (P<0.0001); sustained MRD negativity ≥12 months 48.7% vs 26.3% (P<0.0001). Risk of progression or death was 43% lower with D-VRd (HR 0.57, 95% CI 0.41-0.79, P=0.0005). Level 2. A dedicated MRD analysis is Zweegman et al., Blood Adv 2026 (PMID 42234958).

    Full text

  • Level 3myelomapositive2024

    Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)

    Fan H, Wang B, Shi L, Pan N, et al.. Clin Cancer Res. PMID 38170583. EasyM clonotypic serum mass spectrometry

    Method and clinical-monitoring paper for EasyM, a peripheral-blood clonotypic mass-spectrometry assay tracking serum M-protein for MRD in myeloma.

    Full text

  • Level 3myelomapositive2025

    Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma

    Zhao J, Khong T, Gorniak M, Khaled A, et al.. Haematologica. PMID 39506908. EasyM (serum MS) vs EuroFlow NGF (bone marrow)

    Head-to-head comparison of the blood-based EasyM clonotypic mass-spectrometry assay with EuroFlow bone-marrow MRD in myeloma (Haematologica 2025). The PubMed record did not include a structured abstract with numeric concordance rates at retrieval, so rates are not restated here; the paper and DOI were verified.

    Full text

  • Level 1myelomapending2019

    SWOG S1803 DRAMMATIC: daratumumab-lenalidomide vs lenalidomide maintenance with MRD-adapted duration in newly diagnosed myeloma after transplant

    SWOG / NCI NCTN. ClinicalTrials.gov. MRD-adapted maintenance duration

    Ongoing randomized MRD-adapted maintenance trial. No primary efficacy results paper was identified as of this review. Included as a level-1-design trial (MRD-integral randomization) without outcome data.

  • Level 2myelomapositive2026

    Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS

    Zweegman S, Facon T, Hungria V, Bahlis NJ, et al.. Blood Adv. PMID 42234958. MRD at 10^-5 and 10^-6, including sustained MRD negativity · n=395

    395 patients (D-VRd 197, VRd 198), median follow-up 58.7 months. Overall MRD-negativity 10^-5: 60.9% vs 39.4% (OR 2.37, 95% CI 1.58-3.55, P<.0001); 10^-6: 46.2% vs 27.3% (OR 2.24, 95% CI 1.48-3.40, P=0.0001). Sustained MRD negativity ≥12 months 10^-5: 49.2% vs 27.3%; 10^-6: 34.0% vs 16.2% (each P<.0001), with similar benefits at ≥24 and ≥36 months. Among patients who achieved MRD negativity, PFS trended in favor of D-VRd (10^-5 HR 0.61, 95% CI 0.35-1.06, P=0.0755).

    Full text

HemeMyelomaTier 3PinnedMRD / ctDNAFDAGuidelines

FDA draft guidance describes bone-marrow MRD negativity plus complete response as an accelerated-approval endpoint in myeloma

On January 21, 2026, the FDA released draft guidance on using minimal residual disease and complete response in multiple myeloma to support accelerated approval, defining the MRD endpoint as bone-marrow negativity by flow cytometry or sequencing in patients who have achieved complete response or stringent complete response, and noting that the April 12, 2024 ODAC unanimously accepted MRD as an accelerated-approval endpoint.

Federal Register